VINEETLAB
Small CapVineet Laboratories Limited
Pharma
Vineet Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, management trust is a red flag, price trend is neutral, and recent execution is weak.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Dec 2025
Bad · 0/100Rev -14% YoY · margin expansion
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹15.7 Cr | -13.5% | -10.2% |
| EBITDA | ₹2.5 Cr | +160.0% | -22.0% |
| Operating margin | 15.8% | +3867 bps | -240 bps |
| PAT | ₹0.9 Cr | NDF | +112.5% |
| PAT margin | 5.4% | +3698 bps | +313 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Issuer presentation review pending
Vineet Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Dec 2025. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trend score and candlestick chart
53NeutralSMA20 +2.3% / mo
Technical chart
VINEETLABweekly · 1Y+12.4%Technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 48. Wait for confirmation.
- SMA20 rising (~2.2% over last month) — short-term momentum positive.
- RSI(14) at 48 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 30% off 52W high · 21% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
OVERVALUEDWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- FCF yield is supportive at 12.0%.
- Cash flow contributes 7/10 to the score.
- Valuation contributes 3/30 to the score.
Main drags
- Altman Z is 1.1, in distress territory.
- Penalty bucket subtracts 8 points.
- Growth is weaker at 0/25; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Weak Trust: Claim history is still being built. It ranks around the 1st percentile of the scored universe and 2nd percentile within Pharma. Main check: results consistency is weak at 19/100.
Low Trust Lite: Promoter pledge is zero. Key concern: Promoter holding fell 23.3%.
Management or financial behaviour needs caution. Demand stronger valuation compensation.
overall median 67 · Pharma: 2nd pctile, median 70 · Small: 1st pctile, median 65
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Weak Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is 11.5%.
Trust risks
- ▸Promoter holding fell 23.3%.
- ▸Debt/equity is 3.07.
- ▸Altman Z is 1.10.
- ▸3 recent quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- —
- P/B
- 4.70
- EV/EBITDA
- —
- Market Cap
- 66.80Cr
Profitability
- ROE
- -89.50%
- ROCE
- -28.00%
- ROA
- -10.99%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -9.00%
- EPS 5Y
- -9.00%
- Revenue 3Y
- -27.00%
- EPS 3Y
- -7.00%
Balance Sheet
- Debt/Equity
- 3.07
- Interest Coverage
- -1.00×
- Altman Z
- 1.08
- Book Value
- 7.40
Cash Flow
- FCF Yield
- 11.98%
- FCF Positive Y
- 3/5
- OCF
- 11.00 Cr
- EPS TTM
- -5.28
Shareholding
- Promoter Hold
- 5.98%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 55%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.